Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia

• Published in: International journal of hyperthermia Vol. 15; no. 6; pp. 475 - 486
• Main Authors: LARUE, S. M, FOX, M. H, OGILVIE, G. K, PAGE, R. L, GETZY, D. M, THRALL, D. E, JOHNSON, J. L, DEWHIRST, M. W, GILLETTE, E. L
• Format: Journal Article
• Language: English
• Published: London Informa UK Ltd 01.11.1999; Taylor & Francis
• Subjects: Animals; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Cell Cycle; Combined Modality Therapy; Dog Diseases - drug therapy; Dog Diseases - therapy; Dogs; Doxorubicin - administration & dosage; Hyperthermia, Induced; Indazoles - administration & dosage; Induced hyperthermia. Cryotherapy; Lymphoma - drug therapy; Lymphoma - therapy; Lymphoma - veterinary; Medical sciences; Predictive Assays;Brdurd;Tpot;Labelling Index;Non-hodgkin's Lymphoma; Prognosis; Treatment with physical agents; Treatment. General aspects; Tumors; Antineoplastic agent; Fissipedia; Carnivora; Treatment efficiency; Malignant hemopathy; Non Hodgkin lymphoma; Vertebrata; Chemotherapy; Mammalia; Lymphoproliferative syndrome; Animal; Combined treatment; Kinetics; Whole body; Predictive factor; Dog; Tumor cell; Induced hyperthermia
• ISSN: 0265-6736; 1464-5157
• DOI: 10.1080/026567399285477

Kinetic parameters including potential doubling time (T pot), duration of S phase (T s), labelling index (LI), and DNA index (DI) were obtained from 42 dogs with previously untreated lymphoma. Standard flow cytometric techniques using BrdUrd were employed. All dogs were treated with L-asparaginase and remission was induced in 26 dogs, which were then randomized to receive chemotherapy only (doxorubicin [DOX]alone or with lonidamine) or chemotherapy plus whole body hyperthermia (WBH). Dogs were treated every 3 weeks for up to five treatments and evaluated every 3 weeks for evidence of tumour recurrence. Within this subset of animals there was no difference in outcome based on treatment group. Median values for T pot, T s and LI were 3.4 days, 7.23h and 12.49%, respectively. Dogs that had tumours with LI 20% had a shorter time until recurrence than dogs with tumours characterized by LI< 20%. In dogs treated only with chemotherapy, dogs bearing tumours with longer than median T pot and T s values and lower than median LI had significantly longer remission duration than dogs with more rapidly proliferating tumours. Dogs treated only with chemotherapy, which had longer than median T pot and T s values and lower than median LI, had significantly longer remission duration than all other dogs in the study. The mechanisms in which kinetics are associated with response to chemotherapy are not clear and vary depending on tumour type and treatment regimen. More work is needed to understand factors involved in cell killing during in vivo hyperthermia.